Overview
The gut microbiota is considered to constitute a "microbial organ" which has pivotal roles in the intestinal diseases and body's metabolism. Evidence from animal and human studies strongly supports the link between intestinal bacteria and inflammatory bowel diseases (IBD). Dozens of studies reported its efficacy in treatment of severe Clostridium difficile colitis. Preliminary studies using FMT for Ulcerative Colitis (UC), Crohn's diseases (CD), irritable bowel syndrome (IBS) and constipation have also met with some success. However, the results on CD is very limited. This is an initial step into investigating the potential efficacy of fecal bacteriotherapy for CD, the investigators propose to determine the efficiency, durability and safety of FMT in a series of 500 patients with CD in ten years.
Description
The present clinical trial aims to re-establish a gut functionality state of intestinal flora through FMT as a therapy for CD (all age range,HBI>4). We established a standard microbiota isolation from donated fresh stool in lab. Then the microbiota is transplanted to mid-gut (at least below the duodenal papilla) through regular gastroscope. Patients from multi-clinical centers in this study will be assigned to receive FMT only once or traditional treatments according to associated guidelines and follow-up for at least one year. Blood tests, abdominal X-ray, endoscopy and questionnaire will be used to assess participants at study start and at study completion.
Eligibility
Inclusion Criteria:
patients who had been diagnosed with CD through a combination of typical clinical symptoms,
endoscopy, and histological criteria for at least 3 months, patients with inactive and
active CD and patients who failed to achieve satisfactory efficacy for CD from the previous
therapies.
Exclusion Criteria:
Patients were excluded if accompanied by other severe diseases, including other intestinal
diseases (e.g., Clostridioides difficile infection), malignant neoplasm, cardiopulmonary
failure, and serious liver and kidney disease, refused to complete the follow-up, and
underwent FMT or WMT before.